KR102607599B1 - 인플루엔자의 치료 방법 - Google Patents

인플루엔자의 치료 방법 Download PDF

Info

Publication number
KR102607599B1
KR102607599B1 KR1020197024919A KR20197024919A KR102607599B1 KR 102607599 B1 KR102607599 B1 KR 102607599B1 KR 1020197024919 A KR1020197024919 A KR 1020197024919A KR 20197024919 A KR20197024919 A KR 20197024919A KR 102607599 B1 KR102607599 B1 KR 102607599B1
Authority
KR
South Korea
Prior art keywords
influenza
virus
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197024919A
Other languages
English (en)
Korean (ko)
Other versions
KR20190112051A (ko
Inventor
게리 에워트
캐롤린 루스콤베
Original Assignee
바이오트론 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017900385A external-priority patent/AU2017900385A0/en
Application filed by 바이오트론 리미티드 filed Critical 바이오트론 리미티드
Publication of KR20190112051A publication Critical patent/KR20190112051A/ko
Application granted granted Critical
Publication of KR102607599B1 publication Critical patent/KR102607599B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197024919A 2017-02-08 2018-02-07 인플루엔자의 치료 방법 Active KR102607599B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2017900385 2017-02-08
AU2017900385A AU2017900385A0 (en) 2017-02-08 Methods of treating influenza
PCT/AU2018/050085 WO2018145148A1 (en) 2017-02-08 2018-02-07 Methods of treating influenza

Publications (2)

Publication Number Publication Date
KR20190112051A KR20190112051A (ko) 2019-10-02
KR102607599B1 true KR102607599B1 (ko) 2023-11-28

Family

ID=63106827

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197024919A Active KR102607599B1 (ko) 2017-02-08 2018-02-07 인플루엔자의 치료 방법

Country Status (12)

Country Link
US (1) US10918623B2 (https=)
EP (1) EP3579833B1 (https=)
JP (1) JP7019727B2 (https=)
KR (1) KR102607599B1 (https=)
CN (1) CN110325187B (https=)
AU (1) AU2018218179B2 (https=)
BR (1) BR112019016316A2 (https=)
ES (1) ES2910136T3 (https=)
MX (1) MX387115B (https=)
RU (1) RU2769317C2 (https=)
SG (1) SG11201907034PA (https=)
WO (1) WO2018145148A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
DK3785717T3 (da) 2015-09-16 2022-03-21 Gilead Sciences Inc Fremgangsmåder til behandling af coronaviridae-infektioner
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ， インコーポレイテッド ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
TW202344257A (zh) 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
WO2022251318A1 (en) 2021-05-26 2022-12-01 Gilead Sciences, Inc. Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
JP2024543259A (ja) * 2021-11-24 2024-11-20 バイオトロン リミティッド ＳＡＲＳ－ＣｏＶ－２感染を治療する方法
KR20240154646A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
JP2025508941A (ja) 2022-03-03 2025-04-10 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス化合物並びにその作製及び使用方法
KR20240155326A (ko) 2022-03-03 2024-10-28 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물 및 이의 제조와 사용 방법
US20240009220A1 (en) 2022-06-06 2024-01-11 Gilead Sciences, Inc. Methods for treatment of viral infections
WO2024006376A1 (en) 2022-06-29 2024-01-04 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
EP4547665A1 (en) 2022-06-30 2025-05-07 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2024173458A1 (en) 2023-02-16 2024-08-22 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
AU2024330988A1 (en) 2023-08-31 2026-02-19 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
WO2025054278A1 (en) 2023-09-06 2025-03-13 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US20250109157A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543886A (ja) 2005-06-24 2008-12-04 バイオトロン リミテッド 抗ウイルス化合物および方法
CN110870864A (zh) 2018-08-29 2020-03-10 复旦大学 马来酸卡比沙明在制备抗流感病毒药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100254942A1 (en) * 2007-08-03 2010-10-07 Biotron Limited Hepatitis c antiviral compositions and methods
KR101369584B1 (ko) * 2011-04-19 2014-03-06 일양약품주식회사 페닐-이속사졸 유도체 및 그의 제조방법
AU2015287994B2 (en) * 2014-07-07 2020-03-12 Prophylaxis, Llc Viral prophylaxis treatment methods and pre-exposure prophylaxis kits

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008543886A (ja) 2005-06-24 2008-12-04 バイオトロン リミテッド 抗ウイルス化合物および方法
US20140066487A1 (en) 2005-06-24 2014-03-06 Biotron Limited Antiviral compounds and methods
US20160376231A1 (en) 2005-06-24 2016-12-29 Biotron Limited Antiviral compounds and methods
CN110870864A (zh) 2018-08-29 2020-03-10 复旦大学 马来酸卡比沙明在制备抗流感病毒药物中的应用

Also Published As

Publication number Publication date
SG11201907034PA (en) 2019-08-27
WO2018145148A1 (en) 2018-08-16
NZ755900A (en) 2025-03-28
US20200093796A1 (en) 2020-03-26
ES2910136T3 (es) 2022-05-11
EP3579833B1 (en) 2022-01-05
RU2769317C2 (ru) 2022-03-30
CN110325187B (zh) 2022-09-30
CN110325187A (zh) 2019-10-11
MX387115B (es) 2025-03-19
MX2019009443A (es) 2019-12-16
AU2018218179B2 (en) 2023-05-04
EP3579833A1 (en) 2019-12-18
JP2020506243A (ja) 2020-02-27
RU2019126746A3 (https=) 2021-05-28
KR20190112051A (ko) 2019-10-02
US10918623B2 (en) 2021-02-16
AU2018218179A1 (en) 2019-08-22
JP7019727B2 (ja) 2022-02-15
EP3579833A4 (en) 2021-01-13
BR112019016316A2 (pt) 2020-03-31
CA3052503A1 (en) 2018-08-16
RU2019126746A (ru) 2021-03-09

Similar Documents

Publication Publication Date Title
KR102607599B1 (ko) 인플루엔자의 치료 방법
Tarbet et al. Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in mice
EA037529B1 (ru) Способ получения соединения для ингибирования репликации вирусов гриппа
JP2020196704A (ja) インフルエンザウイルス感染症またはコロナウイルス感染症の予防および／または治療剤
EP3934653B1 (en) Azelastine as antiviral treatment
US10221152B2 (en) Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus
RU2597150C2 (ru) Противовирусное соединение множественного действия, его состав и способ лечения вирусных заболеваний
CN118574614A (zh) 治疗sars-cov-2感染的方法
CA3052503C (en) Methods of treating influenza
CN114377009A (zh) Sb216763在制备抗流感病毒药物中的应用
HK40017310B (en) Methods of treating influenza
HK40017310A (en) Methods of treating influenza
WO2019089734A1 (en) Methods and compositions for the treatment of influenza
CN102112461B (zh) 新型二芳基庚酮系化合物及其应用
TWI530284B (zh) 馬替麥考酚酯或其鹽類用於製備抗流感病毒之藥物的用途
Lozitsky Anti-Infectious Actions of Proteolysis Inhibitor e-Aminocaproic Acid (ε-ACA)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190826

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210128

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230414

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230908

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231124

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231124

End annual number: 3

Start annual number: 1

PG1601 Publication of registration